Advertisement

Molecular Medicine

, Volume 16, Issue 9–10, pp 425–432 | Cite as

MTHFR, MTR, and MTRR Polymorphisms in Relation to p16INK4A Hypermethylation in Mucosa of Patients with Colorectal Cancer

  • Yvonne Wettergren
  • Elisabeth Odin
  • Göran Carlsson
  • Bengt Gustavsson
Research Article

Abstract

We recently analyzed the hypermethylation status of the p16INK4a (p16) gene promoter in normal-appearing mucosa obtained from patients with colorectal cancer. Hypermethylation of p16 was associated with reduced survival of these patients. In the present study, germ line polymorphisms in the folate- and methyl-associated genes, methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR) and methionine synthase reductase (MTRR), were analyzed in the same patient cohort to find a possible link between these genetic variants and p16 hypermethylation. Genomic DNA was extracted from blood of patients (n = 181) and controls (n = 300). Genotype analyses were run on an ABI PRISM® 7900HT sequence-detection system (Applied Biosystems), using real-time polymerase chain reaction and TaqMan chemistry. The results showed that the genotype distributions of the patient and control groups were similar. No significant differences in cancer-specific or disease-free survival of stage I–III patients according to polymorphic variants were detected, nor were any differences in cancer-specific or disease-free survival detected when patients were subgrouped according to the MTHFR or MTR genotype groups and dichotomized by p16 hypermethylation status in mucosa. However, patients with the MTRR 66 AA/AG genotypes were found to have a significantly worse cancer-specific survival when the mucosa were positive, compared with negative, for p16 hypermethylation (hazard ratio 2.7; 95% confidence interval 1.2–6.4; P = 0.023). In contrast, there was no difference in survival among patients with the MTRR 66 GG genotype stratified by p16 hypermethylation status. These results indicate a relationship between genetic germ-line variants of the MTRR gene and p16 hypermethylation in mucosa, which may affect the clinical outcome of patients with colorectal cancer.

Notes

Acknowledgments

We acknowledge the technical skills of M Martinsson, M Åkerström and J Flach. We thank H Björkqvist and A-L Helminen for collecting surgical tissue samples and L Munro, B Sjöberg and M-L Jakobsson for their work with the clinical database. We also thank the staff at the Genomics Core Facility in Gothenburg who performed the genotype analyses.

This work was supported by grants from the Swedish Cancer Society, the University of Gothenburg Foundation, the Assar Gabrielsson Foundation for Cancer Research, the Gustaf V Jubilee Clinic Foundation for Cancer Research and the Ingabritt and Arne Lundberg Foundation.

References

  1. 1.
    Sharpless NE. (2005) INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 576:22–38.CrossRefGoogle Scholar
  2. 2.
    Alhaja E, et al. (2004) Anti-migratory and antiangiogenic effect of p16: a novel localization at membrane ruffles and lamellipodia in endothelial cells. Angiogenesis. 7:323–33.CrossRefGoogle Scholar
  3. 3.
    Wettergren Y, Odin E, Nilsson S, Carlsson G, Gustavsson B. (2008) p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer. Mol. Med. 14:412–21.CrossRefGoogle Scholar
  4. 4.
    Ulrich CM, et al. (2005) MTHFR variants reduce the risk of G:C->A:T transition mutations within the p53 tumor suppressor gene in colon tumors. J. Nutr. 135:2462–7.CrossRefGoogle Scholar
  5. 5.
    Oyama K, Kawakami K, Maeda K, Ishiguro K, Watanabe G. (2004) The association between methylenetetrahydrofolate reductase polymorphism and promoter methylation in proximal colon cancer. Anticancer Res. 24:649–54.PubMedGoogle Scholar
  6. 6.
    Mato JM, Lu SC. (2005) Homocysteine, the bad thiol. Hepatology. 41:976–9.CrossRefGoogle Scholar
  7. 7.
    Peyrin-Biroulet L, et al. (2007) Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine. Am. J. Gastroenterol. 102:1108–15.CrossRefGoogle Scholar
  8. 8.
    Toffoli G, et al. (2003) Methylenetetrahydrofolate reductase 677 C—>T polymorphism and risk of proximal colon cancer in north Italy. Clin. Cancer Res. 9:743–8.PubMedGoogle Scholar
  9. 9.
    Koushik A, et al. (2006) Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 15:2408–17.CrossRefGoogle Scholar
  10. 10.
    Fernandez-Peralta AM, et al. (2010) Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy. Int. J. Colorectal Dis. 25:141–51.CrossRefGoogle Scholar
  11. 11.
    Marugame T, et al. (2003) Relation of plasma folate and methylenetetrahydrofolate reductase C677T polymorphism to colorectal adenomas. Int. J. Epidemiol. 32:64–6.CrossRefGoogle Scholar
  12. 12.
    Sharp L, Little J. (2004) Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am. J. Epidemiol. 159:423–43.CrossRefGoogle Scholar
  13. 13.
    Keku T, et al. (2002) 5,10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol. Biomarkers Prev. 11:1611–21.PubMedGoogle Scholar
  14. 14.
    Shannon B, Gnanasampanthan S, Beilby J, Iacopetta B. (2002) A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut. 50:520–4.CrossRefGoogle Scholar
  15. 15.
    Plaschke J, Schwanebeck U, Pistorius S, Saeger HD, Schackert HK. (2003) Methylenetetrahydrofolate reductase polymorphisms and risk of sporadic and hereditary colorectal cancer with or without microsatellite instability. Cancer Lett. 191:179–85.CrossRefGoogle Scholar
  16. 16.
    Lima CS, et al. (2007) Polymorphisms in methylenetetrahydrofolate reductase gene (MTHFR) and the age of onset of sporadic colorectal adenocarcinoma. Int. J. Colorectal. Dis. 22:757–63.CrossRefGoogle Scholar
  17. 17.
    Cohen V, et al. (2003) Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 9:1611–5.PubMedGoogle Scholar
  18. 18.
    Etienne MC, et al. (2004) Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics. 14:785–792.CrossRefGoogle Scholar
  19. 19.
    Derwinger K, Wettergren Y, Odin E, Carlsson G, Gustavsson B. (2009) A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin. Colorectal Cancer. 8, 43–8.CrossRefGoogle Scholar
  20. 20.
    Chua W, et al. (2009) Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br. J. Cancer. 101:998–1004.CrossRefGoogle Scholar
  21. 21.
    van der Put NM, et al. (1997) Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease. QJM. 90:511–7.CrossRefGoogle Scholar
  22. 22.
    Leclerc D, et al. (1996) Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum. Mol. Genet. 5:1867–74.CrossRefGoogle Scholar
  23. 23.
    Harmon DL, et al. (1999) Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet. Epidemiol. 17:298–309.CrossRefGoogle Scholar
  24. 24.
    Paz MF, et al. (2002) Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res. 62:4519–24.PubMedGoogle Scholar
  25. 25.
    Kang S, et al. (2005) Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol. Oncol. 96:173–80.CrossRefGoogle Scholar
  26. 26.
    Zijno A, et al. (2003) Folate status, metabolic genotype, and biomarkers of genotoxicity in healthy subjects. Carcinogenesis. 24:1097–103.CrossRefGoogle Scholar
  27. 27.
    Wilson A, et al. (1999) A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol. Genet. Metab. 67:317–23.CrossRefGoogle Scholar
  28. 28.
    Olteanu H, Munson T, Banerjee R. (2002) Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 41:13378–85.CrossRefGoogle Scholar
  29. 29.
    de Vogel S, et al. (2009) Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 18:3086–96.CrossRefGoogle Scholar
  30. 30.
    Hubner RA, et al. (2006) Folate metabolism polymorphisms influence risk of colorectal adenoma recurrence. Cancer Epidemiol. Biomarkers Prev. 15:1607–13.CrossRefGoogle Scholar
  31. 31.
    Yamaji T, et al. (2009) Methionine synthase A2756G polymorphism interacts with alcohol and folate intake to influence the risk of colorectal adenoma. Cancer Epidemiol. Biomarkers Prev. 18:267–74.CrossRefGoogle Scholar
  32. 32.
    Kraunz KS, et al. (2006) Dietary folate is associated with p16(INK4A) methylation in head and neck squamous cell carcinoma. Int. J. Cancer. 119:1553–7.CrossRefGoogle Scholar
  33. 33.
    Kamiya H, et al. (1998) A methylenetetrahydrofolate reductase polymorphism is associated with expression of p16 in human lung cancer. Oncol. Rep. 5:911–4.PubMedGoogle Scholar
  34. 34.
    Hamilton SR, Aaltonen LA. (2000) Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC press. 314 pp.Google Scholar
  35. 35.
    Compton CC, et al. (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124:979–94.PubMedGoogle Scholar
  36. 36.
    Herman JG, et al. (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:4525–30.PubMedGoogle Scholar
  37. 37.
    Belshaw NJ, et al. (2008) Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br. J. Cancer. 99:136–42.CrossRefGoogle Scholar
  38. 38.
    Chen LC, et al. (2004) Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res. 64:3694–700.CrossRefGoogle Scholar
  39. 39.
    Gloria L, et al. (1996) DNA hypomethylation and proliferative activity are increased in the rectal mucosa of patients with long-standing ulcerative colitis. Cancer. 78:2300–6.CrossRefGoogle Scholar
  40. 40.
    Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI. (2008) Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 266:6–11.CrossRefGoogle Scholar
  41. 41.
    Tanaka T, Iwasa Y, Kondo S, Hiai H, Toyokuni S. (1999) High incidence of allelic loss on chromosome 5 and inactivation of p15INK4B and p16INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene. 18:3793–7.CrossRefGoogle Scholar
  42. 42.
    Toyokuni S. (2008) Molecular mechanisms of oxidative stress-induced carcinogenesis: from epidemiology to oxygenomics. IUBMB Life. 60:441–7.CrossRefGoogle Scholar
  43. 43.
    Romanenko A, et al. (2002) P16INK4A and p15INK4B gene alteration associated with oxidative stress in renal cell carcinomas after the chernobyl accident (pilot study). Diagn. Mol. Pathol. 11:163–9.CrossRefGoogle Scholar
  44. 44.
    Belinsky SA, et al. (2002) Aberrant CpG island methylation of the p16(INK4a) and estrogen receptor genes in rat lung tumors induced by particulate carcinogens. Carcinogenesis. 23:335–9.CrossRefGoogle Scholar
  45. 45.
    Govindarajan B, et al. (2002) Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol. Med. 8:1–8.CrossRefGoogle Scholar
  46. 46.
    Jang TJ, Kim DI, Shin YM, Chang HK, Yang CH. (2001) p16(INK4a) promoter hypermethylation of non-tumorous tissue adjacent to gastric cancer is correlated with glandular atrophy and chronic inflammation. Int. J. Cancer. 93:629–34.CrossRefGoogle Scholar
  47. 47.
    O’Byrne KJ, Dalgleish AG. (2001) Chronic immune activation and inflammation as the cause of malignancy. Br. J. Cancer. 85:473–83.CrossRefGoogle Scholar
  48. 48.
    van Engeland M, et al. (2003) Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 63:3133–7.PubMedGoogle Scholar
  49. 49.
    Tchantchou F. (2006) Homocysteine metabolism and various consequences of folate deficiency. J. Alzheimers Dis. 9:421–7.CrossRefGoogle Scholar
  50. 50.
    Rogers EJ, Chen S, Chan A. (2007) Folate deficiency and plasma homocysteine during increased oxidative stress. N. Engl. J. Med. 357:421–2.CrossRefGoogle Scholar
  51. 51.
    Morgenstern I, Raijmakers MT, Peters WH, Hoensch H, Kirch W. (2003) Homocysteine, cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with inflammatory bowel disease. Dig. Dis. Sci. 48:2083–90.CrossRefGoogle Scholar
  52. 52.
    Danese S, et al. (2005) Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am. J. Gastroenterol. 100:886–95.CrossRefGoogle Scholar
  53. 53.
    Peyrin-Biroulet L, et al. (2008) Association of MTRR 66A>G polymorphism with superoxide dismutase and disease activity in patients with Crohn’s disease. Am. J. Gastroenterol. 103:399–406.CrossRefGoogle Scholar
  54. 54.
    Chen J, et al. (2002) Linkage disequilibrium between the 677C>T and 1298A>C polymorphisms in human methylenetetrahydrofolate reductase gene and their contributions to risk of colorectal cancer. Pharmacogenetics. 12:339–42.CrossRefGoogle Scholar
  55. 55.
    Giovannucci E, et al. (2003) Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 12:970–9.PubMedGoogle Scholar
  56. 56.
    Curtin K, et al. (2004) MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol. Biomarkers Prev. 13:285–92.CrossRefGoogle Scholar
  57. 57.
    Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M. (2006) Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother. Pharmacol. 57:835–40.CrossRefGoogle Scholar
  58. 58.
    Zintzaras E, et al. (2009) MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics. 10:1285–94.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2010

Authors and Affiliations

  • Yvonne Wettergren
    • 1
  • Elisabeth Odin
    • 1
  • Göran Carlsson
    • 1
  • Bengt Gustavsson
    • 1
  1. 1.Surgical-Oncology Laboratory Department of General SurgeryUniversity of Gothenburg, Plan 1, CK, Sahlgrenska University Hospital/ÖstraGothenburgSweden

Personalised recommendations